Trial Profile
A Phase I, Randomised, Single-blind, Single-centre, Incomplete-block Crossover, Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Dec 2010
Price :
$35
*
At a glance
- Drugs Zibotentan (Primary)
- Indications Non-small cell lung cancer; Prostate cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2008 New trial record.